Key Points
- COO Kathleen Goin sold 4,302 Palvella shares for approximately $654,807 at an average price of $152.21 under a pre-arranged Rule 10b5-1 plan, reducing her direct holdings by 66.64% to 2,154 shares.
- Palvella reported quarterly EPS of -$1.52, missing the consensus estimate of -$1.17; analysts expect a full-year loss of approximately $6.36 per share.
- Despite the insider sale and losses, institutional ownership stands at 40.11%, while analysts maintain a consensus “Buy” rating with an average price target of $209.14 versus the stock’s $142.58 opening price.
Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) COO Kathleen Goin sold 4,302 shares of the company's stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $152.21, for a total value of $654,807.42. Following the transaction, the chief operating officer directly owned 2,154 shares in the company, valued at approximately $327,860.34. This represents a 66.64% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Kathleen Goin also recently made the following trade(s):
- On Wednesday, June 17th, Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock. The shares were sold at an average price of $110.73, for a total value of $476,360.46.
Palvella Therapeutics Stock Performance
NASDAQ PVLA opened at $142.58 on Friday. The stock has a fifty day moving average of $141.68 and a 200-day moving average of $124.34. The stock has a market capitalization of $2.05 billion, a P/E ratio of -29.52 and a beta of -0.17. Palvella Therapeutics, Inc. has a 52 week low of $48.65 and a 52 week high of $161.38.
Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.35). Equities research analysts forecast that Palvella Therapeutics, Inc. will post -6.36 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Palvella Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in PVLA. Millennium Management LLC bought a new stake in shares of Palvella Therapeutics in the 1st quarter valued at $7,553,000. Goldman Sachs Group Inc. acquired a new stake in Palvella Therapeutics during the 1st quarter worth $533,000. Geode Capital Management LLC lifted its holdings in Palvella Therapeutics by 84.7% during the second quarter. Geode Capital Management LLC now owns 173,986 shares of the company's stock worth $3,923,000 after acquiring an additional 79,787 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Palvella Therapeutics by 108,066.7% in the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company's stock valued at $73,000 after acquiring an additional 3,242 shares during the period. Finally, Rhumbline Advisers acquired a new position in Palvella Therapeutics in the second quarter valued at about $224,000. 40.11% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
Several analysts have weighed in on the company. HC Wainwright reissued a "buy" rating and set a $270.00 price objective on shares of Palvella Therapeutics in a report on Wednesday, July 22nd. Truist Financial set a $207.00 target price on shares of Palvella Therapeutics in a research note on Wednesday, August 5th. Canaccord Genuity Group set a $232.00 price target on shares of Palvella Therapeutics in a research report on Wednesday, August 5th. Chardan Capital upgraded shares of Palvella Therapeutics to a "strong-buy" rating in a research report on Tuesday, July 28th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Palvella Therapeutics in a research note on Monday, June 29th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $209.14.
Check Out Our Latest Research Report on PVLA
Palvella Therapeutics Company Profile
(
Get Free Report)
Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.
Palvella's pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
